Role of Glucosamine and Chondroitin in the Prevention of Cancer: A Meta-Analysis

References

• Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29(7):1304–12. doi: 10.1158/1055-9965.EPI-19-1534.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Willett WC. Balancing life-style and genomics research for disease prevention. Science. 2002;296:695–8.
   PubMed Web of Science ®Google Scholar
• Cimmino L, Neel BG, Aifantis I. Vitamin C in stem cell reprogramming and cancer. Trends Cell Biol. 2018;28(9):698–708. doi: 10.1016/j.tcb.2018.04.001.
   PubMed Web of Science ®Google Scholar
• Mikkelsen SU, Gillberg L, Lykkesfeldt J, Grønbaek K. The role of vitamin C in epigenetic cancer therapy. Free Radic Biol Med. 2021;170:179–93. doi: 10.1016/j.freeradbiomed.2021.03.017.
   PubMed Web of Science ®Google Scholar
• Miller KL, Clegg DO. Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am. 2011;37(1):103–18. doi: 10.1016/j.rdc.2010.11.007.
   PubMed Web of Science ®Google Scholar
• Sherman AL, Ojeda-Correal G, Mena J. Use of glucosamine and chondroitin in persons with osteoarthritis. PM R. 2012;4(5 Suppl):S110–S6. doi: 10.1016/j.pmrj.2012.02.021.
   PubMedGoogle Scholar
• Bruyère O, Altman RD, Reginster J-Y. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S12–S7. doi: 10.1016/j.semarthrit.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, Berenbaum F, Blanco FJ, Conaghan PG, Doménech G, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75(1):37–44. doi: 10.1136/annrheumdis-2014-206792.
   PubMed Web of Science ®Google Scholar
• Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018;320:2564–79. doi: 10.1001/jama.2018.19319.
   PubMed Web of Science ®Google Scholar
• McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA. 2000;283(11):1469–75. 10.1001/jama.283.11.1469
   PubMed Web of Science ®Google Scholar
• Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867–78. doi: 10.1001/jama.2008.892.
   PubMed Web of Science ®Google Scholar
• Sakai S, Sugawara T, Kishi T, Yanagimoto K, Hirata T. Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci. 2010;86(9-10):337–43. doi: 10.1016/j.lfs.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Xu C-X, Jin H, Chung Y-S, Shin J-Y, Woo M-A, et al. Chondroitin sulfate extracted from the Styela clava tunic suppresses TNF-alpha-induced expression of inflammatory factors, VCAM-1 and iNOS by blocking Akt/NF-kappaB signal in JB6 cells. Cancer Lett. 2008;264(1):93–100. doi: 10.1016/j.canlet.2008.01.022.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol. 2012;176(11):1002–13. doi: 10.1093/aje/kws186.
   PubMed Web of Science ®Google Scholar
• Lee DH, Cao C, Zong X, Zhang X, O’Connell K, Song M, Wu K, Du M, Cao Y, Giovannucci EL, et al. Glucosamine and chondroitin supplements and risk of colorectal adenoma and serrated polyp. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2693–701. doi: 10.1158/1055-9965.EPI-20-0805.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statis Med. 2002;21:1539–58.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. 10.1016/0197-2456(86)90046-2
   PubMedGoogle Scholar
• Greenlee H, White E, Patterson RE, Kristal AR. Supplement use among cancer survivors in the Vitamins and Lifestyle (VITAL) study cohort. J Altern Complement Med. 2004;10:660–6.
   PubMed Web of Science ®Google Scholar
• van Tonder E, Herselman MG, Visser J. The prevalence of dietary-related complementary and alternative therapies and their perceived usefulness among cancer patients. J Hum Nutr Diet. 2009;22(6):528–35. doi: 10.1111/j.1365-277X.2009.00986.x.
   PubMed Web of Science ®Google Scholar
• Conway RE, Rigler FV, Croker HA, Lally PJ, Beeken RJ, Fisher A. Dietary supplement use by individuals living with and beyond breast, prostate, and colorectal cancer: a cross-sectional survey. Cancer. 2022;128(6):1331–8. doi: 10.1002/cncr.34055.
   PubMed Web of Science ®Google Scholar
• Luo Q, Asher GN. Use of dietary supplements at a comprehensive cancer center. J Altern Complement Med. 2018;24(9-10):981–7. doi: 10.1089/acm.2018.0183.
   PubMed Web of Science ®Google Scholar
• Greenlee H, Kwan ML, Ergas IJ, Sherman KJ, Krathwohl SE, Bonnell C, Lee MM, Kushi LH. Complementary and alternative therapy use before and after breast cancer diagnosis: the Pathways Study. Breast Cancer Res Treat. 2009;117(3):653–65. doi: 10.1007/s10549-009-0315-3.
   PubMed Web of Science ®Google Scholar
• Harrigan M, McGowan C, Hood A, Ferrucci LM, Nguyen T, Cartmel B, Li F-Y, Irwin ML, Sanft T. Dietary supplement use and interactions with tamoxifen and aromatase inhibitors in breast cancer survivors enrolled in lifestyle interventions. Nutrients. 2021;13(11):3730. doi: 10.3390/nu13113730.
   PubMed Web of Science ®Google Scholar
• Alsanad SM, Howard RL, Williamson EM. An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement Altern Med. 2016;16(1):393. 10.1186/s12906-016-1372-x
   PubMed Web of Science ®Google Scholar
• Sibbritt D, Adams J, Lui C-W, Broom A, Wardle J. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One. 2012;7(7):e41540. doi: 10.1371/journal.pone.0041540.
   PubMed Web of Science ®Google Scholar
• Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1419–28. doi: 10.1158/1055-9965.EPI-09-0038.
   PubMed Web of Science ®Google Scholar
• Ibáñez-Sanz G, Guinó E, Morros R, Quijada-Manuitt MÁ, de la Peña-Negro LC, Moreno V. Chondroitin sulphate and glucosamine use depend on nonsteroidal anti-inflammatory drug use to modify the risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1809–16. doi: 10.1158/1055-9965.EPI-19-1051.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Newton CC, Giovannucci EL, McCullough ML, Campbell PT, Jacobs EJ. Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2018;29(3):389–97. doi: 10.1007/s10552-018-1003-6.
   PubMed Web of Science ®Google Scholar
• Kantor ED, O’Connell K, Liang PS, Navarro SL, Giovannucci EL, Du M. Glucosamine use and risk of colorectal cancer: results from UK Biobank. Cancer Epidemiol Biomarkers Prev. 2022;31(3):647–53. doi: 10.1158/1055-9965.EPI-21-1171.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Miguel A, García-Rodríguez LA, Gil M, Barreira-Hernández D, Rodríguez-Martín S, de Abajo FJ. Population-based case-control study: chemoprotection of colorectal cancer with non-aspirin nonsteroidal anti-inflammatory drugs and other drugs for pain control. Aliment Pharmacol Ther. 2019;50(3):295–305. doi: 10.1111/apt.15333.
   PubMed Web of Science ®Google Scholar
• Ibáñez-Sanz G, Díez-Villanueva A, Vilorio-Marqués L, Gracia E, Aragonés N, Olmedo-Requena R, Llorca J, Vidán J, Amiano P, Nos P, et al. Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study. Sci Rep. 2018;8(1):2040. doi: 10.1038/s41598-018-20349-6.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Lampe JW, Peters U, Shen DD, Vaughan TL, White E. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control. 2013;24(6):1137–46. doi: 10.1007/s10552-013-0192-2.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Zhang X, Wu K, Signorello LB, Chan AT, Fuchs CS, Giovannucci EL. Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: results from the Nurses’ Health Study and Health Professionals follow-up study. Int J Cancer. 2016;139(9):1949–57. doi: 10.1002/ijc.30250.
   PubMed Web of Science ®Google Scholar
• Brasky TM, Kristal AR, Navarro SL, Lampe JW, Peters U, Patterson RE, White E. Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort. Nutr Cancer. 2011;63(4):573–82. doi: 10.1080/01635581.2011.553022.
   PubMed Web of Science ®Google Scholar
• Hotaling JM, Wright JL, Pocobelli G, Bhatti P, Porter MP, White E. Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. J Urol. 2011;185(4):1210–5. doi: 10.1016/j.juro.2010.11.081.
   PubMed Web of Science ®Google Scholar
• Brasky TM, Lampe JW, Slatore CG, White E. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 2011;22(9):1333–42. doi: 10.1007/s10552-011-9806-8.
   PubMed Web of Science ®Google Scholar
• Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1696–708. doi: 10.1158/1055-9965.EPI-10-0318.
   PubMed Web of Science ®Google Scholar
• Walter RB, Brasky TM, Milano F, White E. Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2298–308. doi: 10.1158/1055-9965.EPI-11-0494.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang X, Liu Y, Zhang J, Li L, Huang X, Thabane L, Lip GYH. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. Eur Respir J. 2022;59(3):2101399. doi: 10.1183/13993003.01399-2021.
   PubMed Web of Science ®Google Scholar
• Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291(5):585–90. 10.1001/jama.291.5.585
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ, Virtamo J, Taylor PR, Albanes D, Sinha R, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66(4):2483–7.
   PubMed Web of Science ®Google Scholar
• Siemes C, Visser LE, Coebergh J-WW, Splinter TAW, Witteman JCM, Uitterlinden AG, Hofman A, Pols HAP, Stricker BHC. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006;24(33):5216–22.
   PubMed Web of Science ®Google Scholar
• Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56(2):69–83. 10.3322/canjclin.56.2.69
   PubMed Web of Science ®Google Scholar
• Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol. 2009;6(5):327–34. doi: 10.1038/cmi.2009.43.
   PubMed Web of Science ®Google Scholar
• Man X, Piao C, Lin X, Kong C, Cui X, Jiang Y. USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer. J Exp Clin Cancer Res. 2019;38:259. doi: 10.1186/s13046-019-1262-4.
   PubMed Web of Science ®Google Scholar
• De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34(27):3493–503. doi: 10.1038/onc.2014.286.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhan L, Cao H, Li J, Lyu Y, et al. Increased mitochondrial fission promotes autophagy and hepatocellular carcinoma cell survival through the ROS-modulated coordinated regulation of the NFKB and TP53 pathways. Autophagy. 2016;12(6):999–1014. doi: 10.1080/15548627.2016.1166318.
   PubMed Web of Science ®Google Scholar
• Largo R, Alvarez-Soria MA, Díez-Ortego I, Calvo E, Sánchez-Pernaute O, Egido J, Herrero-Beaumont G. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003;11(4):290–8.
   PubMed Web of Science ®Google Scholar
• Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 2005;26(6):318–25. 10.1016/j.it.2005.04.003
   PubMed Web of Science ®Google Scholar
• Largo R, Martínez-Calatrava MJ, Sánchez-Pernaute O, Marcos ME, Moreno-Rubio J, Aparicio C, Egido J, Herrero-Beaumont G. Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol Heart Circ Physiol. 2009;297(1):H268–H276. doi: 10.1152/ajpheart.00142.2009.
   PubMed Web of Science ®Google Scholar
• Bak Y-K, Lampe JW, Sung M-K. Effects of dietary supplementation of glucosamine sulfate on intestinal inflammation in a mouse model of experimental colitis. J Gastroenterol Hepatol. 2014;29(5):957–63. doi: 10.1111/jgh.12485.
   PubMed Web of Science ®Google Scholar
• Navarro SL, White E, Kantor ED, Zhang Y, Rho J, Song X, Milne GL, Lampe PD, Lampe JW. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015;10(2):e0117534. doi: 10.1371/journal.pone.0117534.
   PubMed Web of Science ®Google Scholar
• Kantor ED, Lampe JW, Navarro SL, Song X, Milne GL, White E. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014;20(6):479–85. doi: 10.1089/acm.2013.0323.
   PubMed Web of Science ®Google Scholar
• Kantor ED, O’Connell K, Du M, Cao C, Zhang X, Lee DH, Cao Y, Giovannucci EL. Glucosamine and chondroitin use in relation to C-reactive protein concentration: results by supplement form, formulation, and dose. J Altern Complement Med. 2021;27(2):150–9. doi: 10.1089/acm.2020.0283.
   PubMed Web of Science ®Google Scholar
• Sanaki Y, Nagata R, Kizawa D, Léopold P, Igaki T. Hyperinsulinemia drives epithelial tumorigenesis by abrogating cell competition. Dev Cell. 2020;53(4):379–89. doi: 10.1016/j.devcel.2020.04.008.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–48. doi: 10.1152/physrev.00030.2014.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50. doi: 10.1016/S0140-6736(10)61543-7.
   PubMed Web of Science ®Google Scholar
• Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WC, Fuchs CS. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004;140(3):157–66.
   PubMed Web of Science ®Google Scholar